REGN Stock: Price, Earnings History and SEC Filings
Regeneron Pharmaceuticals, Inc. (REGN) last traded at $927.89, up 13.33% on the latest session and up 22.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $12.53 against an analyst estimate of $8.00, a beat of 56.6%.
$927.89 +13.33%
1 month+22.37%
52-week high$935.35
52-week low$591.52
Volume2.87M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
REGN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $12.53 | $8.00 | +56.62% |
| Mar 2026 | Apr 29, 2026 | $7.50 | $6.28 | +19.43% |
| Dec 2025 | Jan 30, 2026 | $9.30 | $8.28 | +12.32% |
| Sep 2025 | Oct 28, 2025 | $9.63 | $7.52 | +28.06% |
REGN beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for REGN
SEC filing data is not available right now. You can search for REGN on SEC EDGAR.
REGN news
- Regeneron (REGN) Stock Looks At A Discount To EarningsOct 31, 2026 · finance.yahoo.com
- Why Regeneron Shares Are In Focus After Strong EarningsOct 31, 2026 · finance.yahoo.com
- Regeneron: 3 Key Takeaways for Long-Term InvestorsOct 31, 2026 · fool.com
- Regeneron Stock Just Hit a 2-Year High. Here's Why.Oct 31, 2026 · barchart.com
- Regeneron Pharmaceuticals (REGN) Jumped, But What Is The Market Seeing Now?Oct 31, 2026 · finance.yahoo.com
- Regeneron (REGN) stock trades up, here is whyOct 31, 2026 · finance.yahoo.com
- Regeneron Bolts 13% Higher, Breaking Out To A Two-Year High On Dupixent DominanceOct 30, 2026 · finance.yahoo.com
- US Equity Markets End Lower After Sell-Off in Technology StocksOct 30, 2026 · finance.yahoo.com
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) is a US-listed public company on Nasdaq.